Poster Session 1 – Tuesday, December 6, 2022: 5:00 pm CT
   
  Treatment - Adjuvant Therapy: Adjuvant Chemotherapy
P1-01-01 The role of adjuvant chemotherapy for elderly women with triple-negative breast cancer
Lan T, Guo Q, Lu Y, Gu J, Shao X, Xu H, Hu Z. Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China; The First People’s Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, China.
P1-01-02 The impact of adjuvant chemotherapy on overall survival in hormone and node positive breast cancer patients with an Oncotype Dx score of 25 or less. A NCDB analysis
Ashok Kumar P, Huang D, Sivapiragasam A, Wang D. SUNY Upstate Medical University, Syracuse, NY.
P1-01-03 The impact of comorbid HIV infection on neoadjuvant and adjuvant chemotherapy relative dose intensity in South African breast cancer patients
O'Neil DS, Ayeni OA, Farrow Woolridge HA, Chen WC, Demetriou G, Buccimazza I, Cacala S, Joffe M, Pumpalova Y, Mapanga W, Jacobson JS, Crew KD, Neugut AI, Ruff P, Cubasch H. University of Miami Miller School of Medicine; Wits Health Consortium/Soweto Comprehensive Cancer Centre, Johannesburg, South Africa; Wits Health Consortium; University of the Witwatersrand; University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital and Wits Donald Gordon Medical Center; Inkosi Albert Luthuli Central Hospital; Ngwelezana Hospital, Empangeni, KZN, South Africa; University of Miami; Sylvester Comprehensive Cancer Center at the University of Miami; Columbia University; Faculty of Health Sciences, University of the Witwatersrand; Columbia University Irving Medical Center; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University; University of Witwatersrand, Faculty of Health Sciences; Wits University, Johannesburg, SA.
P1-01-04 Comparing the effects of TC and Anthracycline-based chemotherapy in women with breast cancer HER2 negative treated in the adjuvant setting – An individual patient meta-analysis
Giffoni M. M. Mata D, Smowton M. Sunnybrook Health Sciences Centre; Michael Garron Hospital.
P1-01-05 Adjuvant S-1 plus endocrine therapy for estrogen receptor-positive, HER2-negative, primary breast cancer: updated overall survival analysis from the POTENT trial
Takada M, Saji S, Ueno T, Masuda N, Ishiguro H, Ishida T, Saeki T, Imoto S, Ohno S, Iwata H, Sugie T, Aogi K, Mukai H, Takayama S, Sato N, Kai Y, Kitada M, Nakamura R, Matsuyama Y, Toi M. Kyoto University Graduate School of Medicine; Fukushima Medical University; Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Nagoya University Graduate School of Medicine, Department of Surgery, Breast Oncology NHO Osaka National Hospital; Saitama Medical University International Medical Center; Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine; Breast Oncology Service, Saitama Medical University International Medical Center; Kyorin University Hospital; Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research; Aichi Cancer Center Hospital, Aichi, Japan; Breast Surgery, Kansai Medial University Hospital; Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center; Department of Medical Oncology, National Cancer Center Hospital East; Department of Breast Surgery, National Cancer Center Hospital; Department of Breast Oncology, Niigata Cancer Center Hospital; Ueo Breast Cancer Hospital; Breast Disease Center, Asahikawa Medical University Hospital; Division of Breast Surgery, Chiba Cancer Center; Department of Biostatistics, School of Public Health, The University of Tokyo; Graduate School of Medicine , Kyoto University.
P1-01-06 Differences in breast tumor response to neoadjuvant chemotherapy by race- Is obesity the key?
Rumano R, Grimm M, Palettas M, Stephens J, Williams N, Sardesai S, Quiroga D, Ramaswamy B, Paskett E, Oppong B. The Ohio State University Comprehensive Cancer Center; The Ohio State University Wexner Medical Center; The Ohio State University.
P1-01-07 Adjuvant and neoadjuvant chemotherapy for treatment of early and locally advanced breast cancer in the elderly population at a UK tertiary cancer centre
Chung A, Sheri A, King J, Newby J, Chopra N. Royal Free Hospital NHS Foundation Trust, London, United Kingdom.
   
  Treatment - Adjuvant Therapy: Adjuvant Endocrine Therapy
P1-02-01 Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis
Janni W, Untch M, Harbeck N, Gilgorov J, Jacot W, Chia SK, Boileau J-F, Haftchenary S, Gupta R, Mishra N, Pathak P, Curigliano G. Department Gynecology and Obstetrics, University of Ulm, Germany; Helios Klinikum Berlin-Buch, Berlin, Germany; Breast Center, Department of Obstetrics and Gynecology, and CCC Munich, LMU University Hospital, Munich, Germany; Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Paris, France; Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Paris, France; British Columbia Cancer Agency, Vancouver, BC, Canada; Jewish General Hospital Segal Cancer Centre, McGill University, Montréal, Quebec, Canada; Novartis Pharmaceuticals Canada, Montreal, QC, Canada; Novartis Healthcare Pvt Ltd, Hyderabad, India; Novartis Pharmaceuticals, East Hanover, NJ USA; European Institute of Oncology, IRCCS, University of Milano, Milan, Italy.
P1-02-02 Withdrawn
P1-02-03 Real world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Sukumar JS, Sardesai S, Ni A, Williams N, Ramaswamy B, Wesolowski R, Cherian MA, Stover DG, Gatti-Mays M, Pariser AC, Sudheendra PK, George MA, Lustberg M. MD Anderson Cancer Center; The Ohio State University Comprehensive Cancer Center; The Ohio State University College of Public Health; James Cancer Hospital and the Ohio State University Comprehensive Cancer Center; Rutgers Cancer Institute of New Jersey; Yale Cancer Center.
P1-02-04 Real world adjuvant endocrine treatment in premenopausal breast cancer patients compared with the proposed algorithm using the Regan Composite Risk Score
Berteloot C, Neven P, Vangoitsenhoven M, Laenen A, Wildiers H, Punie K, Smeets A, Nevelsteen I, Han S, Baert T, Janssen H, Oldenburger E, Baten A, Berteloot P, Vanhoudt R, Deblander A, Remmerie C, Desmedt C. KU Leuven; Universitair Ziekenhuis Leuven, Leuven, Belgium; University Hospitals Leuven / RZ Tienen; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Belgium; Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; UZ Leuven; Multidisciplinary Breast Cancer Center (MBC), University Hospitals Leuven, Leuven, Belgium; Laboratory for Translation Breast Cancer Research/KU Leuven.
P1-02-05 Endocrine-targeted therapies modify the gut microbiome affecting responsiveness in ER+ breast cancer
Arnone A, Wilson AS, Chiba A, Kerr B, Soto-Pantoja DR, Thomas A, Cook KL. Wake Forest University School of Medicine; Wake Forest School of Medicine; Duke University Medical Center; Atrium Health Wake Forest Baptist Health.
P1-02-06 Improved survival with ovarian function suppression in premenopausal hormone receptor-positive breast cancer: a propensity score matching of ASTRRA-trial participants with single-center postmenopausal patients
Lee Y-j, Yoo T-K, Lee SB, Kim J, Chung I-Y, Ko BS, Lee JW, Son BH, Ahn SH, Kim S, Kim HJ. Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Department of Clinical Epidemiology and Biostatistics, Asan Medical Center.
P1-02-07 Moved to OT1-01-02
P1-02-08 CBD-oil: a potential solution in case of severe tamoxifen-related side effects
Buijs S, Braal L, Buck S, van Maanen NF, van der Meijden-Erkelens L, Kuijper-Tissot van Patot H, Oomen-de Hoop E, Saes L, van den Boogerd S, Struik L, van Rossum-Schornagel Q, Mathijssen R, Koolen S, Jager A. Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Clinical Cannabis Care, Breukelen, The Netherlands; Alexander Monro Hospital, Bilthoven, The Netherlands; Ikazia Hospital, Rotterdam, The Netherlands; Franciscus Gasthuis & Vlietland, Schiedam, The Netherlands.
P1-02-09 Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial
Haddad TC, Suman V, Giridhar KV, Moreno-Aspitia A, Northfelt D, Ernst B, Sideras K, O'Sullivan CC, Singh R, Desta Z, Taraba J, Goodnature B, Goetz MP, Wang L, Ingle JN. Mayo Clinic, Rochester, MN, USA; Indiana University School of Medicine; Mayo Clinic Breast Cancer Specialized Program of Research Excellence.
   
  Treatment - Advanced Disease Treatment: Advanced Chemotherapy
P1-03-01 Eribulin versus S-1 as first- or second- line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomized controlled trial
Kikawa Y, Kashiwabara K, Taira N, Iwatani T, Shimozuma K, Ohtani S, Yoshinami T, Watanabe J, Kashiwaba M, Watanabe K-i, Kitada M, Sakaguchi K, Tanabe Y, Aihara T, Mukai H, Takahashi M. Kansai Medical University Hospital; The University of Tokyo Hospital; Kawasaki Medical School; Okayama University Hospital; Ritsumeikan University; Ohotani_S Breast Clinic; Osaka University Hospital; Juntendo University Graduate School of Medicine; Adachi breast clinic; NHO Hokkaido Cancer Center; Breast Disease Center, Asahikawa Medical University Hospital; Kyoto Prefectural University of Medicine; Toranomon Hospital; Aihara Hospital; Department of Medical Oncology, National Cancer Center Hospital East; Hokkaido University, Sapporo, Japan.
P1-03-02 Efficacy of eribulin mesylate in HER2-low and HER2-0 metastatic breast cancer (MBC): Results from an analysis of two phase 3 studies
Twelves C, Kaufman PA, Awada A, Im S-A, Lalayan B, Xie R, Vahdat LT, Cortés J. University of Leeds/Leeds Teaching Hospitals Trust, Leeds, United Kingdom; University of Vermont Cancer Center, Burlington, VT, USA; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Seoul National University College of Medicine, Seoul, Korea, Republic of (South); Eisai Inc., Nutley, NJ, USA; Dartmouth Cancer Center, Lebanon, NH, USA; International Breast Cancer Center (IBCC), Barcelona, Spain.
P1-03-03 Real-world treatment patterns and clinical outcomes in patients treated with Eribulin after prior PI3K inhibitor therapy for metastatic breast cancer
Goyal RK, Zhang J, Davis KL, Kaufman PA. RTI Health Solutions; Eisai Inc.; University of Vermont Cancer Center, Burlington, VT, USA.
P1-03-04 Visceral fat area as a predictive factor in metastatic HER2 negative breast cancer patients treated by first line chemotherapy with weekly paclitaxel and bevacizumab
Guiu S, Guiu B, Chevrier M, Billa O, Levy C, Trédan O, Desmoulins I, Debled M, Ferrero J-M, Jouannaud C, Gonçalves A, Rios M, Mouret-Reynier M-A, Berger F, Toumi F-Z, Lemonnier J, Pierga J-Y, Dabakuyo S, Gourgou S. Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, INSERM U1194, Montpellier, France; CHU Montpellier; Institut Curie; Centre Georges-François Leclerc; Centre François Baclesse; Medical Oncology Department, Centre Léon Bérard, Lyon, France; Institut Bergonié; Centre Antoine Laccassagne; Institut Godinot; Institut Paoli-Calmettes; Institut De Cancerolgie De Lorraine - Alexis Vautrin; Centre Jean Perrin; Institut Curie; R&D Unicancer; Institut Curie & Université Paris Cité; Institut régional du Cancer, Montpellier.
P1-03-05 Overview of the management and factors associated with outcomes of metastatic breast cancer among elderly patients
Vidaurre Mendes S, Zanin Orsi B, Monteiro Vasconcellos J, Araujo Neto A, Andrade Rocha E, Messias AP, Noschang Moreira O, Galvão Freire PJ, Vecchi Leis L, Baptista Pereira M, Petry V, Colombo Bonadio R, Testa L. Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.
   
  Prognostic and Predictive Factors: Predictive Biomarkers for Combined Modality Therapies
P1-04-01 High HER2/CEP17 ratio is associated with better treatment outcomes in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 2+ or 3+ results
Seo J, Koh J, Lee D-W, Ryu HS, Lee H-H, Kim T-Y, Im S-A. Seoul National University Hospital; Seoul National University College of Medicine, Seoul, Korea, Republic of (South).
P1-04-02 Gut microbiome diversity correlates with tumor PD-L1 status in metastatic triple negative breast cancer (mTNBC): correlative analysis of gut microbiome and tumoral biomarkers
Chun B, Goodyear S, Rice-Stitt T, Karstens L, Dahl E, Li A, Hobbs E, Zahi M. Knight Cancer Institute, Oregon Health & Science University; Bioinformatics and Computational Biomedicine, Oregon Health & Science University; Sutter Health; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University.
P1-04-03 Withdrawn
P1-04-04 A multiomic approach to the identification of immune signatures of anti-PD1/PDL1 therapy responders in metastatic triple negative breast cancer: new implications in the role of helper T-cell and B-cell interplay
Wilkerson AD, Rayman PA, Pavicic Jr PG, Husic H, Makarov V, Juric I, Chan T, Montero AJ, Diaz-Montero M. Cleveland Clinic Foundation; Cleveland Clinic; Cleveland Clinic Lerner COM-CWRU; UH/Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA; Immunomonitoring Laboratory Lerner Research Institute Cleveland Clinic.
P1-04-05 Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial
Waks A, Ogayo ER, Paré L, Marín-Aguilera M, Brasó-Maristany F, Galvan P, Castillo O, Martínez-Sáez O, Vivancos A, Villagrasa P, Tarantino P, Desai N, Guerriero JL, Metzger O, Tung N, Krop I, Parker JS, Perou CM, Prat A, Winer EP, Tolaney SM, Mittendorf EA. Dana-Farber Cancer Institute; Reveal Genomics; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS); Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain ; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Breast Oncology Program, Dana-Farber Cancer Institute; Harvard Medical School; North Carolina; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center, Boston; Yale Cancer Center, New Haven, CT; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Breast Cancer Unit, IOB-Quirón Salud, Barcelona, Spain; Yale Cancer Center; Smilow Cancer Network (previously: Medical Oncology, Dana-Farber Cancer Institute; Breast Oncology Program, Dana-Farber Brigham Cancer Center; Harvard Medical School); Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
P1-04-06 Characterization of recurrence risk after lumpectomy and radiotherapy in HER2-positive ductal carcinoma in situ of the breast, using 7-gene predictive biosignature: Implications for the NSABP-B43 trial results
Vicini F, Shah C, Rabinovitch R, Whitworth P, Margenthaler JA, Czerniecki BJ, Dabbs DJ, Weinmann S, Leo M, Mann GB, Wärnberg F, Savala J, Shivers SC, Mittal K, Bremer T. GenesisCare; Cleveland Clinic; University of Colorado Cancer Center; University of Tennessee; Washington University School of Medicine; H. Lee Moffitt Cancer Center; University of Pittsburgh Medical Center; Kaiser Permanent Center for Health Research; The Royal Melbourne Hospital; Gothenburg University, Sweden; PreludeDx.
P1-04-07 pCR Score: a novel prognostic method to estimate the predictive probability of pCR in early-stage breast cancer patients
Peterson J, Cole Jr JA, Berry DA, Cook D, Howard FM, Nanda R, Wolf C, Gabani PS, Takiar V, Kuzmiak C, Carey LA, Fox D, Chalasani P, Antony AK. SimBioSys, Inc.; Berry Consultants, LLC; University of Chicago, Chicago, IL, USA; Northwest Community Healthcare; Baylor Scott & White Health; University of Cincinnati, College of Medicine; University of North Carolina, Lineberger Comprehensive Cancer Center; Alliance for Clinical Trials in Oncology; Springfield Clinic; University of Arizona Cancer Center.
P1-04-08 Independent validation of a novel, non-invasive approach to predict pathologic complete response (pCR) in a blinded, prospectively-run single center trial
Kuzmiak C, Hartman TS, Benefield T, Peterson J, Antony AK, Pandey T, Cole Jr JA, Calhoun BC, Carey LA. University of North Carolina, Lineberger Comprehensive Cancer Center; University of North Carolina, Department of Radiology; SimBioSys, Inc.; University of North Carolina, Department of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center; Alliance for Clinical Trials in Oncology.
P1-04-09 Correlating predicted adjuvant therapy benefit and risk of recurrence between Breast Cancer Index (BCI) and 21-gene oncotype DX Recurrence Score (RS)
Patel R, Casasanta N, Li Z, Kier M, Blanter J, Sohval S, Hovstadius M, Wu C, Fink M, Zhou X, Zimmerman B Cascetta K, Chen R, Oh W, Tiersten A. Icahn School of Medicine at Mount Sinai; Sema4; Frank H. Netter MD School of Medicine at Quinnipiac University; Zucker School of Medicine, Northwell.
P1-04-10 Association of stromal tumor infiltrating lymphocytes (sTILs) in pretreatment biopsies in different molecular subtypes of HER2+/ER+ breast cancer: Assessment of NRG Oncology/NSABP B-52
Pogue-Geile KL, Maley SK, Kim RS, Wang Y, Salgado R, Lipchik C, Feng H, Cecchini RS, Jacobs SA, Srinivasan A, Mamounas EP, Geyer Jr CE, Rastogi P, Osborne CK, Paik S, Wolmark N, Lucas PC, Rimawi MF. NSABP; GZA-ZNA-Hospitals, Antwerp, Belgium; Peter Mac Callum Cancer Centre, Melbourne, Australia; University of Pittsburgh; Autism Impact Fund; NRG Oncology and Orlando Health Cancer Institute; UPMC Hillman Cancer Center; NSABP/NRG Oncology and UPMC Hillman Cancer Center/University of Pittsburgh; Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine; UPMC Hillman Cancer Center/University of Pittsburgh and NRG Oncology; UPMC Hillman Cancer Center / NSABP Foundation; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
P1-04-11 Tumor infiltrating lymphocytes in initial HER2-low breast cancer
Fernandes I, Damasceno E, Kaliks R, Corpa M, Schvartsman G. Hospital Israelita Albert Einstein.
P1-04-12 Systemic immune response to a Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC
Blenman K, Marczyk M, Foldi J, Gunasekharan V, Silber ALM, Pusztai L. Yale University; Silesian University of Technology; University of Pittsburgh Medical Center; Yale University Cancer Center, New Haven, CT, USA.
P1-04-13 Withdrawn
P1-04-14 Predicting the likelihood of response in PDL-1 positive metastatic triple negative breast cancer treated with an immune checkpoint inhibitor
Aldrich J, Hu T, Switchenko J, Coskun A, Gokmen-Polar Y, Badve S, Bhave M. Emory University; Georgia Institute of Technology; Winship Cancer Institute of Emory University; Georgia Institute of Technology & Emory University; Emory University School of Medicine, Atlanta, GA, USA.
P1-04-15 Clinical application of 21-gene  breast-cancer assay (Oncotype DX) in early hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer with lymph-node-positive disease
Gasol Cudós A, Morales Murillo S, Tuset Der-Abrain N, Velasco Sánchez A, Vilardell Villellas F, Sánchez Guzmán D, Canosa Morales C, Melé Olivé J, Arbones Cid L. Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain.
P1-04-16 A nomogram based on clinicopathologic factors and pretreatment systemic inflammation response index to predict pathological complete response of neoadjuvant systemic therapy in HER2-positive breast cancer: A dual-center study
Wu HY, Tzeng Y-D, Yang JR, Hung CC. Kaohsiung Veterans General Hospital; Taichung Veterans General Hospital.
P1-04-17 Clinical and pathological differences between HER2 Low and other cancer subtypes in breast cancer patients
Mattar A, Amorim A, Diogenes M, Shida J, Gebrim LH. Perola Byington Hospital.
P1-04-18 Identification of UGT2B family genes as potential biomarkers of response to neoadjuvant therapy in HER2+ breast cancer
Gil-Torralvo A, Benavent M, Dominguez-Cejudo MA, Falcon A, Cejuela M, Vieites B, Molina-Pinelo S, Ruiz Borrego M, de la Haba-Rodríguez J, Queipo MI, Salvador Bofill FJ. Hospital Virgen del Rocio; Medical Oncology Department, Hospital Universitario Virgen del Rocío.Andalusia-Roche Network Mixed Alliance in Precision Medical Oncology Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, University of Seville) (Seville, Spain); Instituto de Biomedicina de Sevilla IBiS. Hospital Universitario Virgen del Rocío / CSIC / US, Molecular and translational research in oncology, Seville, Spain; Virgen del Rocio Hospital (Seville); Instituto de Biomedicina de Sevilla IBiS. Hospital Universitario Virgen del Rocío / CSIC / US, Molecular and translational research in oncology, Seville, Spain; Hospital Universitario Virgen del Rocio, Sevilla, Andalucia, Spain; Instituto Maimonides de Investigacion Biomedica, Hospital Reina Sofia, Universidad de Córdoba. GEICAM Spanish Breast Cancer Group; Servicio de Oncología Hospital Clínico Málaga; Hospital Universitario Virgen del Rocío, Seville, Spain.
   
  Detection/Diagnosis: Detection/Diagnosis - Other
P1-05-01 Withdrawn
P1-05-02 Reducing delays of breast cancer care using an innovative digital health platform
Holmes DR, Pulicharam R. XpediteMD, Inc.
P1-05-03 Prevalence of BRCA1/2 mutations in an underrepresented population of women with breast cancer: Observations from the City of Hope INSPIRE study
Mortimer J, Lindsey SS, Solomon I, Park W, Sturgeon D, Blazer K, Gray S, Bonner J, Xia X, Gruber S. City of Hope; City of Hope National Medical Center, Duarte, CA.
P1-05-04 Physician practice patterns of breast imaging after treatment: Survey of real-world practice
Whittaker M, Farr K, Potluri P, Foster N, Erdrich J, Segar J, Ehsani S, Jiralerspong S, Roe D, Chalasani P. Department of Surgery/University of Arizona; University of Arizona; Baylor University; University of Arizona Cancer Center.
P1-05-06 Establishment of the breast ultrasound support system using deep-learning system
Odani E, Hayashida T, Kikuchi M, Nagayama A, Seki T, Takahashi M, Matsumoto A, Murata T, Watanuki R, Yokoe T, Nakashoji A, Maeda H, Onishi T, Asaga S, Hojo T, Jinno H, Sotome K, Matsui A, Suto A, Imoto S, Kitagawa Y. National Tokyo medical center; Department of Surgery, Keio University School of Medicine; Department of Surgery, Teikyo University School of Medicine; Department of Breast Surgery, National Cancer Center Hospital; Department of Breast Surgery, National Cancer Center Hospital East; Department of Surgery, National Hospital Organization Tokyo Medical Center; Department of Breast Surgery, Kitasato Institute Hospital; Department of Breast Surgery, Kyorin University School of Medicine; Dept. of Breast Oncology, Saitama Medical University International Medical Center; Kyorin University Hospital; Department of Surgery, Keio University School of Medicine.
P1-05-07 Detection of progression or regression of breast cancer by circulating tumor DNA (ctDNA)
Karki J, Ghimire B, Herrman E, Yadav S, Muhsin Chisti M. Internal Medicine, Beaumont Hospital, Royal Oak, Michigan; Mayo Clinic; Oakland University William Beaumont School of Medicine.
P1-05-08 Assessment and diagnosis of breast pathology in young women: What can we learn?
Ramirez SA, Menegaz BA, Roark A, Bonefas E, Sepulveda KA, Thompson AM, Carter S. Baylor College of Medicine; Department of Surgical Oncology, Baylor College of Medicine, Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, USA.
P1-05-09 Targeting treatment to tumor response: demonstration of response monitoring with subsequent impact on treatment choices in real time utilizing a novel technology
Tannenbaum S, Hsu E, Hundal J, Wilkes A, Fergusson A, Mamuya F, Tafas T. Uconn Health; QCDx LLC.
P1-05-10 Referral pathways for breast cancer diagnosis and treatment in Mexico: a physicians’ survey
Vazquez-Juarez D, Andrade-Moreno R, Villarreal-Garza C. Breast Cancer Center, Hospital Zambrano Hellion TecSalud
P1-05-11 Improving the performance of early breast cancer diagnosis by a model combining breast ultrasound with methylation markers in non-invasive circulating tumor DNA
Zhang X, Ye Z, Yin Y, Zeng L, Wang J, Lei S, Bibikova M, Chen Z, Fan J-B, Pang D. Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China; AnchorDx Medical Co., Ltd.
P1-05-12 Evaluation of the benefit of the tumor marker cancer antigen 15–3 (CA 15-3) in different subtypes of metastatic breast cancer
Lindman H, Cederqvist Molin E, Jernling M, Schiza A. Uppsala University Hospital; Uppsala University.
P1-05-13 Clinical impact of whole-body magnetic resonance imaging on subsequent management in luminal/HER2-negative breast cancer patients
Merloni F, Palleschi M, Rossi A, Prochowski Iamurri A, Gianni C, Sarti S, Mannozzi F, Fiori F, Di Menna G, Cecconetto L, Sirico M, Casadei C, Bleve S, Gasperoni L, Casadei R, Tontini L, Romeo A, Barone D, De Giorgi U. Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; Department of Radiology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”; Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”; Oncology Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”; Orthopedic Unit, Morgagni-Pierantoni Hospital, Ausl Romagna, Forlì, Italy; Radiotherapy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”.
P1-05-14 ctDNA in breast milk for early detection of pregnancy associated breast cancer
Saura C, Ortiz C, Arenas EJ, Matito J, Suñol-Camas A, Cordoba O, Martinez-Sabadell A, Garcia-Ruiz I, Miranda I, Morales-Comas C, Carrasco Lopez E, Viaplana C, Peg V, Nuciforo P, Bayo N, Miquel JM, Gomez-Rey M, Villacampa G, Arevalo S, Carmona J, Espinosa-Bravo M, Balmaña J, Dienstmann R, Arribas J, Tabernero J, Sanso M, Vivancos A. Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain; Breast Cancer Program.Vall d´Hebron Institute of Oncology/Vall d'Hebron University Hospital, Barcelona, Spain; VHIO; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d’Hebron Institute of Oncology (VHIO); Hospital Universitari Son Espases; Vall Hebron Institute of Oncology; Hospital Universitari Vall D´Hebron, Universitat Autònoma de Barcelona; Breast Imaging Unit, Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Universitari Vall d'Hebron; Hospital Vall D'Hebron; Vall d'Hebron Hospital.
P1-05-15 DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer
Guirguis MS, Adrada B, Patel M, Perez F, Candelaria R, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HTC, Leung J, Whitman GJ, Lane DL, Scoggins ME, Moseley T, White J, Wei P, Son JB, Hwang K-P, Panthi B, Pagel M, Hunt KK, Thompson AM, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. University of Texas MD Anderson Cancer Center, Houston, TX, USA; Baylor College of Medicine; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center.
P1-05-16 Bioimpedance spectroscopy monitoring reduces long-term clinical lymphedema risk
Boyages J, Vicini F, Shah C. Icon Cancer Care; GenesisCare; Cleveland Clinic.
P1-05-17 Radiomic models based on dynamic contrast-enhanced magnetic resonance imaging predict the immunophenotype reflecting spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer
Jeon SH, Kim S-W, Seo M, Lim YJ. Korea Advanced Institute of Science and Technology; Kyung Hee University Medical Center; Kyung Hee University. ;
P1-05-18 Orphan non-coding RNAs for early detection of breast cancer with liquid biopsy
Cavazos TB, Wang J, Afolabi OI, Huang A, Lam DN, Kilinc S, Wang J, Fish L, Zhao X, Pohl A, Li H, Chau KH, Arensdorf PA, Hormozdiari F, Goodarzi H, Alipanahi B. Exai Bio; University of California, Davis; University of California, San Francisco.
P1-05-19 Impact of the COVID-19 pandemic on the diagnostic pathway of breast cancer in the Netherlands: a population-based study
Wolfkamp W, Meijer J, Van Hoeve J, Veltman J, Siesling S. University of Twente; Netherlands Comprehensive Cancer Organisation (IKNL); Ziekenhuis Groep Twente.
P1-05-20 COVID-19 lockdown resulting in advanced cancer and worse histology at presentation in Hispanics
Hussain J, Roman Souza G, Aldawoodi T, Jameson LC, Rahman L, Agim NC, Gelfond J, Mazo-Canola M. UT Health San Antonio; University of Texas Health MD Anderson Cancer Center; UTHSCSA; UT Health San Antonio Long School of Medicine; UT Health San Antonio; University of Texas at San Antonio; Mays Cancer Center.
P1-05-21 Change in breast cancer detection method, stage at diagnosis and treatment during the COVID-19 Pandemic: 2019-2021
Malmgren JA, Atwood M, Kaplan H. University of Washington; Swedish Cancer Institute.
P1-05-22 The impact of the COVID-19 pandemic on breast cancer diagnoses in San Antonio, TX
Roman Souza G, Aldawoodi T, Hussain J, Jameson LC, Rahman L, Agim NC, Gelfond J, Mazo-Canola M. University of Texas Health MD Anderson Cancer Center; UTHSCSA; UT Health San Antonio; UT Health San Antonio Long School of Medicine; University of Texas at San Antonio; Mays Cancer Center.
P1-05-23 Optimizing the diagnosis of leptomeningeal metastases in breast cancer patients by circulating tumor cells and circulating tumor DNA
Jongbloed EM, Angus L, van den Bent MJ, Jongen JLM, Martens JWM, Van NM, de Weerd V, HM van Deurzen C, Kraan J, Wilting SM, Jager A. Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
P1-05-24 Delays in diagnosis of adolescent and young adult breast cancer and lack of breast health education, community based research
Peters M, Tubman S. Young Breast Cancer Project.
P1-05-25 Clinical and biological features of 158 consecutive and unselected oligometastatic breast cancers
Lacaze JL, Brac de la Perrière C, Ung M, Dalenc F, Nicolai V, De Maio E, Montastruc M, Cabarrou B, Monselet N, Chira C, Glemarec G, Cassou-Mounat T. Institut Universitaire du Cancer Toulouse – Oncopole; Institut Claudius Regaud, IUCT-Oncopole; Institut Claudius Régaud, Toulouse, France; Institut Claudius Regaud / Institut Universitaire du Cancer Toulouse-Oncopole.
P1-05-26 A blood-based lipid panel for personalized risk assessment of breast cancer
Fahrmann J, Irajizad E, Vykoukal J, Gutierrez Barrera A, Dennison J, Wu R, Arun BK, Brewster A, Hanash S. University of Texas MD Anderson Cancer Center.
P1-05-27 Liquid biopsy for HER2 status assessment in breast cancer using surrogate DNA methylation markers
Zhang X, Lu S, Li H, Liu X, Wang J, Zeng L, Lu Z, Liu S, Yin Y, Bibikova M, Chen Z, Fan J-B, Pang D. Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China; AnchorDx Medical Co., Ltd.
P1-05-28 Decreases in circulating tumor associated cells predicts PFS and OS in a pooled analysis of phase I clinical trials using SV-BR-1-GM therapy with or without immune check-point inhibitors in metastatic breast cancer patients
Adams D, Chang M, Lopez-Lago M, Tang C-M, Williams W, Del Priore G. Creatv Microtech, Inc.; BriaCell Therapeutics Corp.
P1-05-29 Breast cancer laterality: Is age a factor?
Elleson K, Sokol GH, Sun W, Whiting J, Lee MC, Czerniecki BJ, Loftus L. H. Lee Moffitt Cancer Center; Uniformed Services University of the Health Sciences.
P1-05-30
Concordance of preoperative breast MRI finding with definitive postoperative pathology report,
after neoadjuvant systemic treatment in patients with breast cancer

Tecic Vuger A, Peric Balja M, Jaksic P, Linaric P, Pavlovic Mavic M, Vazdar L, Separovic R. Division for Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center; Division for Oncology Pathology and Cytology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center; Division for Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center; Jurja Dobrile University Pula; JJ Strossmayera University Osijek.
P1-05-31 A single center retrospective analysis of 259 cases of metaplastic breast cancer
Liu D, Chen J, Hao S, Xiu B, Zhang Q, Zhang L, Liu G, Shao Z, Wu J. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China.
P1-05-32 Outcomes of diagnostic breast imaging in young women (less than 50 years old)
Dehar N, Samuel JN, Jabs D, Hopman W, Mates M. Cancer Center of South Eastern Ontario; Queen's University; Kingston Health Science Center.
P1-05-33 RNA in extracellular vesicles used for the prediction of distant metastasis of breast cancer and the function of TGM2 in promoting breast cancer development
Wu J, Chi Y. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China.
P1-05-34 MicroRNAs as prognostic markers in breast cancer
Nguyen AQ, Cunningham C, Okpechi S, Yousefi H, McKinney S, Boulmay B, Garcia A, Alahari S. Louisiana State University Health Science Center- New Orleans; LSUHSC-NO; Louisiana State University, New Orleans, Louisiana.
P1-05-35 Identification of circulating tumor cells captured by the FDA cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations
Ciccioli M, Moore R, Kwang Kim K, Khazan N, Miller MC, Pailhes-Jimenez A-S. ANGLE plc; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
P1-05-36 AI-based smartphone App using a single-lead ECG for automated QTc diagnostics in oncology
Schinköthe T, Tonk CH, Harbeck N, Carmelo V, Gomes Feliciano J, Wuerstlein R, Küemmel S, Schmidt A. CANKADO GmbH, Digital Health, Alte Landstraße 23, 85521, Ottobrunn, Germany; Breast Center, Department of Obstetrics and Gynecology, and CCC Munich, LMU University Hospital, Munich, Germany; Cardiology Department, Hospital da Luz, Av. Lusíada 100, 1500-650 Lisboa, Portugal; Heart Center, Hospital Cruz Vermelha, R. Duarte Galvão 54, 1549-008 Lisboa, Portugal; Breast Center, Dept. OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany; Breast Unit, Kliniken Essen-Mitte, Essen, Germany; Sports Biology, Institute for Sports Science, University of the Bundeswehr Munich, Werner- Heisenberg-Weg 39, 85577, Neubiberg, Germany.
   
  Epidemiology, Risk, and Prevention: Ethnic/Racial Aspects
P1-06-01 Associations of historic and contemporary “redlining” with breast cancer stage at diagnosis
Wiese D, Stroup AM, Jemal A, Henry KA, Islami F. American Cancer Society; New Jersey State Cancer Registry, Rutgers Cancer Institute of New Jersey; Geography and Urban Studies, Temple University.
P1-06-02 The effect of race on pathologic complete response rates and overall survival in patients with triple negative breast cancer
Woriax HE, Thomas SM, Plichta JK, Rosenberger LH, Botty van de bruele A, Chiba A, DiLalla G, Menendez C, Hwang ES, DiNome ML. Duke University School of Medicine; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke University Medical Center.
P1-06-03 Differences in breast cancers among American-Indians and Whites in the United States
Gaba A, Cao L, Renfrew R, Wernisch J, Sahmoun A, Goel S, Crosby R. Sanford Roger Maris Cancer Center; Sanford Health; University of North Dakota, School of Medicine; Rutgers Cancer Institute of New Jersey; Sanford Center for Biobehavioral Research.
P1-06-04 Impacts of treatment delay on breast cancer mortality and benefit of timely care in black and non-black women
Jackson B, Wheeler S, Yanguela J, LeBlanc M, Kuo T-M, Baggett C, Reeder-Hayes K. Cancer Information & Population Health Resource, UNC Lineberger Comprehensive Cancer Center; UNC Department of Health Policy And Management, UNC Lineberger Comprehensive Cancer Center; UNC Gillings School of Global Public Health; UNC Lineberger Comprehensive Cancer Center.
P1-06-05 Withdrawn
P1-06-06 Access to medical coverage in newly diagnosed Breast cancer patients a minority population during the COVID 19 pandemic
Aldawoodi T, Roman Souza G, Hussain J, Jameson LC, Rahman L, Agim NC, Gelfond J, Mazo-Canola M. UTHSCSA; University of Texas Health MD Anderson Cancer Center; UT Health San Antonio; UT Health San Antonio Long School of Medicine; University of Texas at San Antonio; Mays Cancer Center.
P1-06-07 Interrogating the molecular profile of breast cancer tumors in Hispanics living in Puerto Rico (PRH)
Martinez-Viota N, Bittman-Soto X, Montes-Rodriguez IM, Carrasquillo K, Centeno-Girona H, Cruz-Correa M. San Juan Bautista School of Medicine; University of Puerto Rico Comprehensive Cancer Center; University of Puerto School of Medicine.
   
  Prognostic&Predictive Factors:Prognosis-Biomarkers of Natural History-Prog Factors-Clin Testing&Val
P1-07-01 Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with HR+/HER2- early breast cancer: a systematic review and meta-analysis
Martins-Branco D, Molinelli C, Nader Marta G, Ameye L, Paesmans M, Salgado R, Aftimos P, de Azambuja E. Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Data Center, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; GZA-ZNA-Hospitals, Antwerp, Belgium; Peter Mac Callum Cancer Centre, Melbourne, Australia; Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
P1-07-02 Using clinical characteristics and molecular markers to predict the risk of subsequent ipsilateral breast events after excision of DCIS
Liu Y, Strand SH, King L, Harmon B, Couch FJ, Gallagher K, Kilgore M, Wei S, DeMichele A, King T, McAuliffe PF, Marks J, Maley C, West R, Hwang ES, Colditz GA. WUSTL; Stanford; Duke University; Montefiore Medical Center; Mayo Clinic; UNC-CH; University of Washington; University of Alabama at Birmingham; Penn Medicine Abramson Cancer Center, Philadelphia PA, USA; Brigham and Women's Hospital; UPMC Magee-Womens Hospital; Duke University; Arizona State University; Stanford University Medical Center; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Washington University School of Medicine.
P1-07-03 Unmet needs and future applications of breast cancer multigene signatures in routine clinical practice: results from the European PROCURE Project
Gnant M, Lænkholm A-V, Prat A, King J, Curigliano G, Harbeck N, Penault-Llorca F, Cardoso F. Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Zealand University Hospital, Roskilde, Denmark; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Breast Cancer Unit, IOB-Quirón Salud, Barcelona, Spain; Royal Free Hospital NHS Foundation Trust, London, United Kingdom; European Institute of Oncology, IRCCS, University of Milano, Milan, Italy; Breast Center, Department of Obstetrics and Gynecology, and CCC Munich, LMU University Hospital, Munich, Germany; Centre de Lutte Contre le Cancer Jean Perrin, Clermont-Ferrand, France; Brea.st Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
P1-07-04 Claims-derived comorbidities associations with real-world overall survival (rwOS) among patients with metastatic breast cancer in an electronic health record-claims linked dataset
Ascha MS, Asfaw AA, Yerram P, Reiss SN, Brake SD, Wadé NB. Flatiron Health Inc.
P1-07-05 Clinical utility of twenty-five gene-expression profiling using LAMP method in early stage breast cancer
Tsuchida Y, Ueda T, Nagatake Y, Michiyuki S, Hattori M, Sato M, Tomita N, Kanomata N, Yamauchi H. Department of Breast Surgical Oncology; Biochemical Research Laboratory, Research & Development Division, Eiken Chemical Co., Ltd.; Department of Pathology, St. Luke's International Hospital; Department of Breast Surgical Oncology and Department of Clinical Genetics, St. Luke's international hospital.
P1-07-06 Withdrawn
P1-07-07 Cross-talk of four types of RNA modification proteins with adenosine reveals the landscape of multivariate prognostic patterns in breast cancer
Wang X, Xiong M, Xiu B, Wu J, Chi Y. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China.
P1-07-08 Prediction of breast cancer late recurrence according to Clinical Treatment Score post-five years (CTS5) and progesterone receptor in a wider patient population
Carvalho GS, Bretas GO, Musse D, Gondim V, Bines J. Instituto Nacional de Câncer; Grupo Oncoclínicas; Oncologia Dor; Grupo Américas Oncologia/COI; Instituto Nacional de Câncer (INCA).
P1-07-09 Clinical and pathologic characteristics in early breast cancer Her2-low and high risk Oncotype DX RS
Galve E, Pikabea-Diaz F, Lopez-de-San-Vicente-Hernandez B, Figaredo-Berjano C, Legaspi-Folgueira J, Sala-Gonzalez MA, Arango-Arteaga JF, Fernandez-Ferrer S, Loaiza-Jaramillo PL, Casado-Cuesta P, Temino-Frances M, Bilbao-Penas A, Martinez-del-Prado P. Hospital Universitario de Basurto; OSI Bilbao-Basurto; Clínica Vida. Fundación Colombiana de Cancerología. Medellín. Colombia.
   
  Psychosocial, Quality of Life and Educational Aspects-Social and Education Issues: Education
P1-08-01 Virtual molecular and precision medicine (vMAP) clinic to improve access to clinical trials for patients with metastatic breast cancer: an academic-community collaboration
Mortensen L, Keenan JC, Abraham E, Padden S, Ma A, Denault E, Ryan L, Medford AJ, Ellisen LW, Schwartz JH, Bardia A, Spring LM. Massachusetts General Hospital; Cancer Center, Massachusetts General Hospital; Massachusetts General Hospital / UMass Chan Medical School; Massachusetts General Hospital Cancer Center / Dana Farber Cancer Institute; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
P1-08-02 Implementation of integrative medicine program for breast medical oncology professionals in an academic cancer center
Zhi WI, Wanq R, Bao T. Memorial Sloan Kettering Cancer Center.
P1-08-03 Exploratory analysis of a mobile app that addresses radiotherapy informational needs for breast cancer patients
Muñoz Lozano JF, Pérez Ibave DC, Abundis Marquez E, Alcorta Nuñez F, Gonzalez Alcorta CB, Salazar Mejia C, Noriega MF, Zayas Villanueva O, Oyervides Juarez V, Renteria Garcia LM, Alcorta Garza A, Gonzalez Guerrero JF, Luna V, Hernandez D, Piñeiro Retif R, Vidal Gutiérrez O. Hospital Universitario "Jose Eleuterio Gonzalez"; Hospital Universitario; Universidad Autónoma de Nuevo León; ISSSTE; Hospital Universitario.
P1-08-04 Therapeutic advances in metastatic triple-negative breast cancer: Identifying and reducing clinician knowledge gaps
Heller EJ, Smith K, Williams SL. i3 Health.
P1-08-05 Educating pathologists in quantitating stromal tumor-infiltrating lymphocytes in breast cancer for artificial intelligence applications
Garcia V, Ly A, Salgado R, Gallas BD. US Food and Drug Administration; Massachusetts General Hospital; GZA-ZNA-Hospitals, Antwerp, Belgium; Peter Mac Callum Cancer Centre, Melbourne, Australia; U.S. FDA/CDRH/OSEL Division of Imaging, Diagnostics, and Software Reliability.
P1-08-06 Oncology nursing in India: are we up to speed?
Chitkara G, Murali-Nanavati S, Bardeskar N, Gupte A, Behal S, Lad M, Dongarkar P, Shaikh M, Talapatra K. Tata Memorial Hospital; Nanavati Max Super Speciality Hospital, Mumbai, India.
P1-08-07 Educational opportunities to improve HER2 testing and use of newer therapies for HER2-positive MBC among community healthcare professionals
Topping RP, Andrie RM, Rosenthal K, Quill TA. Clinical Care Options.
P1-08-08 Approach to prevention and management of chemotherapy toxicities in a interprofessional education program
Duffy A, Vasaiwala D, Bernhardi C, Lawson J, Rosenblatt P. University of Maryland School of Pharmacy; University of Maryland; University of Maryland Medical Center; University of Maryland School of Medicine.
P1-08-09 DIVAS - DC Pink Divas Intervening Virtually to Advance Saving Lives: Assessing the impact of digital behavioral health breast cancer education program for Black women
Zuend F, Thompson S, Wilson L. DC Pink Divas; Howard University.
P1-08-10 A web-based patient decision aid toolkit for unaffected BRCA mutation carriers
McGarrigle SA, Spillane C, Byrne N, Polus M, Prizeman G, Drury A, Connolly E, Brady A-M, Hanhauser Y. Trinity College Dublin; St. James's Hospital; University College Dublin; St. James's Hospital & Trinity College Dublin.
P1-08-11 Using co-design to develop culturally and linguistically appropriate breast cancer education materials
Rakoff M, Serrano M, Neuhausen S. Breast Cancer Care and Research Fund; City of Hope.
P1-08-12 Improving Cancer-related Symptom Burden and Quality of Life with CancerLife™, a Digital Self-Care Therapeutic for Cancer Patients
Coltman C, Beard I, Irwin SA. Cancerlife.
   
  Treatment - Surgery and Radiotherapy: Breast Conservation
P1-09-01 Withdrawn
P1-09-02 Oncological, cosmetic and quality of life outcomes following breast conservation surgery in patients presenting after non-oncological excsion of breast primary: A prospective follow up study
Irrinki RNNS, Khare S, Singh G, Laroiya I, Mishra A. Postgraduate Institute of Medical Education and Research; PGIMER, Chandigarh; Postgraduate Institute of Medical Education and Research, Chandigarh.
P1-09-03 Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery
Kondo S, Kida K, Suzuki M, Fukano C, Yoshida A, Hayashi N, Takei J, Yamanaka M, Yamauchi H. Department of Breast Surgical Oncology, St. Luke's international hospital; Center for Medical Genetics, St. Luke's international hospital; Department of Breast Surgical Oncology and Department of Clinical Genetics, St. Luke's international hospital; Department of Clinical Genetics and Division of Integrated Women's Health, St. Luke's international hospital.
P1-09-04 Comparison of length and quality of life (QoL ) and the side effects of therapy between breast conserving surgery with intraoperative radiotherapy (TARGIT-IORT) versus mastectomy for in-breast-recurrence of breast cancer
Kolberg H-C, Niesing H, Vaidya JS, Akpolat-Basci L, Maguz A, Hoffmann O, Lövey G, Stephanou M, Kolberg-Liedtke C. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany; Marienhospital Bottrop; University College London; University Hospital Essen; BORAD.
P1-09-05 Effect of wire vs magnetic seed localization on lumpectomy cavity size
Dykstra M, Thompson J, Aldous J, Jiang S, Hughes T, Hayman J, Dragovic A, Shah J, Chang A, Speers CW, Sabel M, Dossett L, Schipper M, Jagsi R. University of Michigan.
P1-09-06 Save the breast after neoadjuvant therapy – identifying radiological and tumor related factors of importance for breast conserving surgery after neoadjuvant chemotherapy
Gulis K, Ellbrant J, Bendahl P-O, Svensjö T, Vallon-Christersson J, Dalene Skarping I, Loman N, Rydén L. Region Skane; Lund University.
P1-09-07 Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
Qu F, Lin C, Li J-J, Shao Z-M. Fudan University Shanghai Cancer Center; Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University.
P1-09-08 Comparisons of aesthetic outcomes and prognosis of conventional breast conserving surgery, oncoplastic breast conserving surgery and breast conserving surgery plus immediate lipofilling in early breast cancer
Ren JH, Wang Y, Zhang X, Wang K, Tang R, Yang L, Gong J, Xu J, Li Q, Zhu WM, Cheng Q, Ren G, Li H. The First Affiliated Hospital of Chongqing Medical University; Department of Oncology-Pathology, Karolinska Institutet Stockholm.
P1-09-09 Salvage mastectomy is not always necessary for aggressive subtypes of ipsilateral breast cancer recurrence: A single-institution retrospective study
Gentile D, Sagona A, Barbieri E, Di Maria Grimaldi S, Spoto R, Franceschini D, Vaccari S, Vinci V, Biondi E, Scardina L, Tinterri C. IRCCS Humanitas Research Hospital; IRCCS A. Gemelli University Polyclinic Foundation.
P1-09-10 Factors associate with borderline or invaded margins in breast cancer surgery at the Val d'Aurelle Montpellier CRLC
Mboua Batoum VM, Dina Bell ED. Yaounde University Hospital; University of Douala.
P1-09-11 Impact of breast surgical procedure on survival in BRCA mutated patients with invasive breast cancer: mastectomy versus conservative treatment
Jankowski C, Mahiou K, Laura V, Costaz H, Padéano M-M, Causeret S, Mamguem A, Dabakuyo S, Coutant C. Centre Georges-François Leclerc, Dijon, FRANCE.
P1-09-12 Withdrawn
   
  Treatment - Surgery and Radiotherapy: Radiotherapy
P1-10-01 Postmastectomy electron beams radiation therapy (PMERT) : long term results
Sami S, Loap P, Fourquet A, Kirova YM. Department of Radiation Oncology, Institut Curie, Paris, France; Institut Curie.
P1-10-02 FLASH-RT, ultra-high dose rate rate radiotherapy, is as effective as conventional dose rate radiotherapy in eradicating tumor in a preclinical model of breast cancer
Dirbas F, Melemenidis S, Loo Jr BL, Horst K, Graves EE, Dutt S, Viswanathan V, Lau B, Yu A. Stanford Cancer Institute; Stanford University School of Medicine; Stanford University.
P1-10-03 Ultra-hypofractionated radiotherapy for breast cancer: A Brazilian single-institutional series
Hernandes de Brito L, Cicci Farinha Restini F, Mansur Starling MT, Silva Moreira de Siqueira G, Nader Marta G, de Andrade Carvalho H, Abdallah Hanna S. Hospital Sirio-Libanês; Hospital Sirio-Libanes, Sao Paulo, Brazil.
P1-10-04 Withdrawn
P1-10-05 Safety of stereotactic body radiation therapy, stereotactic radiosurgery, and other radiation therapy with use of CDK 4/6 inhibitors for hormone receptor positive (HR+), HER2- metastatic breast cancer:  a retrospective cohort study
Chauhan K, Kowalchuk RO, Garda AE, Shumway DA, Waddle MR, Mutter R, Corbin K. Department of Radiation Oncology, Mayo Clinic Rochester Campus; Mayo Clinic; Mayo Clinic, Rochester, MN.
P1-10-06 Carcinoma en Cuirasse Secondary to Locally Advanced Breast Carcinoma: a case report
Liu C-T, Lanier K, Brinkley W. Beaumont Health; Campbell University School of Osteopathic Medicine.
P1-10-07 Role of postmastectomy radiation therapy in breast cancer patients according to pathologic nodal status after neoadjuvant chemotherapy
Kim D, Kim JH, Kim IA, Chang JH, Shin KH. Seoul National University Hospital, Seoul, Korea; Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea.
P1-10-08 Incidence of rib fracture following treatment with proton therapy for breast cancer
Bradley J, Liang X, Mailhot Vega R, Liu C, Brooks E, Burchianti T, Viviers E, Dagan R, Oladeru O, Morris C, Mendenhall N. University of Florida; Mayo Clinic.
P1-10-09 AQP4 inhibition prevents cytotoxic edema of AQP4+ astrocytes but promotes tumor growth of AQP4+ breast cancer brain metastasis
Contreras-Zarate MJ, Alvarez-Eraso K, Tsuji N, Kabos P, Ormond DR, Karam S, Cittelly DM. University of Colorado; University of Colorado Anschutz Medical Campus; University of Colorado Denver, Aurora, CO, USA.
P1-10-10 Radiation treatment patterns for elderly women with breast cancer brain metastases
Upadhyay R, Perlow HK, Williams N, Klamer B, White J, Bazan JG, Jhawar SR, Blakaj DM, Grecula J, Arnett A, Thomas E, Chakravarti A, Raval RR, Lustberg M, Palmer J, Beyer S. The Ohio State University Comprehensive Cancer Center; Ohio State University; Smilow Cancer Hospital, Yale School of Medicine.
P1-10-11 Optical stimulated luminescence dosimeters for skin dose measurements during accelerated partial breast brachytherapy: In vivo dosimetric validation and clinical outcomes
Gutschenritter T, Yorke A, Polissar N, Miljacic N, Kim J, Young L. University of Washington, Department of Radiation Oncology; The Mountain-Whisper-Light: Statistics & Data Science.
P1-10-12 AI-based cardiac sub-structures segmentation for safer radiotherapy planning
Loap P, Botticella A, De Marzi L, Levy A, Bolle S, Colame S, Cannard A, Martineau-Huynh C, Oumani A, Roque TS, Paragios N, Deutsch E, Luo C, Kirova YM, Rivera S. Institut Curie; Gustave Roussy; TheraPanacea; CentraleSupelec. University of Paris-Saclay.
P1-10-13 Economic comparison of standard external beam whole breast (WBI) versus accelerated partial breast irradiation (ABPI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial
Le Bras A, Belkacemi Y, Bourgier C, Gabelle-Flandin I, Petit A, Guilbert P, Geffrelot J, Carrie C, Rivin del Campo E, Hanzen C, Charra-Brunaud C, Auzac G, Lacornerie T, Lemonnier J, Lartigau E, Durand-Zaleski I. APHP Hotel Dieu, Paris; Henri Mondor University Hospital; Gustave Roussy and Institut Cancérologie Montpellier; CHU Grenoble; Institut Bergonié; Centre Francois Baclesse; Centre Leon Berard, Lyon; Hopital Tenon, Paris; Centre Henri Becquerel; Institut de Cancérologie de Lorraine; Gustave Roussy; Centre Oscar Lambret; R&D Unicancer; Centre Oscar Lambret.
P1-10-14 Higher radiation dose to the heart in left sided breast cancer; anatomy versus dosimetry
Alm El-Din M, Niemierko An, Taghian A. Tanta Faculty of Medicine; Massachusetts General Hospital; Harvard Medical School.
P1-10-15 Concious sparing of contralateral thyroid lobe in Ca Breast patients receiving post mastectomy radiotherapy by IMRT technique – A single institution dosimetric study
Chomal M, Iyer M, Kalimurthy A, Sahay J, Banik S. HCG Cancer Centre.
P1-10-16 Cardiac conduction system exposure with modern radiotherapy techniques for breast cancer irradiation
Loap P, Goudjil F, De Marzi L, Servois V, Kirov K, Fourquet A, Kirova YM. Institut Curie.
P1-10-17 Axillary radiotherapy in selected patients with a preoperative diagnosis of lymph node involvement is a safe alternative to axillary lymph node dissection
Arabiyat HA, Brown I, Drew P, English R, Sulieman M, Abbas I, Wheatley D, Potiszil K, Thomson A, King P. Royal Cornwall Hospital; Royal Cornwall NHS Trust.
P1-10-18 Impact of adjuvant chemoradiation on cardiopulmonary function and quality of life in breast cancer
Anup Sr A, Wadasadawala T, Johnny C, Sarin R, Pathak R, Krishnamurthy R, Gupta S, Parmar V, Ghosh J, Bajpai J, Gulia S. Tata Memorial Hospital; Tata Memorial Centre; ACTREC (Advanced Centre for Treatment, Research and Education in Cancer), Maharashtra, India.
   
  Treatment - Therapeutic Strategies: HER2-Targeted Therapy
P1-11-01 Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
Harbeck N, Modi S, Jacot W, Yamashita T, Sohn JH, Vidal M, Tsurutani J, Ueno NT, Prat A, Niikura N, Xu B, Rugo HS, Papazisis K, Cortés J, Krop I, Gambhire D, Yung L, Wang Y, Singh J, Cameron D. Breast Center, Department of Obstetrics and Gynecology, and CCC Munich, LMU University Hospital, Munich, Germany; Memorial Sloan Kettering Cancer Center; Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Paris, France; Kanagawa Cancer Center, Japan; Yonsei Cancer Center, Seoul, Republic of Korea; Medical Oncology Department, Hospital Clínic of Barcelona ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain ; SOLTI Breast Cancer Research Group ; Faculty of Medicine and Health Sciences, University of Barcelona; Advanced Cancer Translational Research Institute at Showa University, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Breast Cancer Unit, IOB-Quirón Salud, Barcelona, Spain; Tokai University School of Medicine, Isehara-shi, Japan; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Euromedica, General Clinic of Thessaloniki, Greece; International Breast Cancer Center (IBCC), Barcelona, Spain; Yale Cancer Center, New Haven, CT; Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; Edinburgh University Cancer Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
P1-11-02 Moved to HER2 Session
P1-11-03 Withdrawn
P1-11-04 Assessing the clinico-pathological characteristics of HER2 positive metastatic breast cancer patients experiencing radiologic complete response in a nationwide cohort
Cucciniello L, Blondeaux E, Bighin C, Gasparro S, Russo S, Dri A, Pugliese P, Fontana A, Naso G, Ferzi A, Riccardi F, Sini V, Boni L, Fabi A, Montemurro F, De Laurentiis M, Arpino G, Del Mastro L, Gerratana L, Puglisi F. Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano; IRCCS Ospedale Policlinico San Martino, Genova; University of Genova, Genova; IRCSS Regina Elena National Cancer Institute, Rome; Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) Udine, Italy; Santa Maria della Misericordia University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine; ASST Lariana, Como; Pisa University Hospital, Pisa; La Sapienza University, Rome; ASST Ovest Milanese, Ospedale di Legnano, Legnano, Italy; Antonio Cardarelli Hospital, Naples; Centro Oncologico S. Spirito-Nuovo Regina Margherita, ASL Roma 1, Rome; IRCCS Ospedale Policlinico San Martino, Genoa; Precision Medicine in Breast Cancer, Fondazione Policlinico Universitario A. Gemelli,IRCCS Rome - Italy; Candiolo Cancer Institute, FPO-IRCCS; Istituto Nazionale dei Tumori IRCCS ‘Fondazione Pascale’, Napoli, Italy; Federico II University Naples - Italy; University of Genova - IRCCS Ospedale Policlinico San Martino; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano; Department of Medicine (DAME), University of Udine, Udine, Italy and Department of Medical Oncology - CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
P1-11-05 Provider perceptions of DESTINY-Breast04, HER2-low directed treatment, and interstitial lung disease
Leon B, Bone R, Jeune-Smith Y, Feinberg B. Cardinal Health Specialty Solutions.
P1-11-06 Multi-omics profiling of HER2-low breast cancer reveals clinically relevant subgroups and therapeutic pathways
Chen L, Liu C-C, Ge J-Y, Shao Z-M, Yu K-d.
P1-11-08 Moved to HER2 Session
P1-11-09 Five year follow up of a randomized phase II comparison of neo-adjuvant docetaxel, carboplatin, trastuzumab with or without lapatinib in HER-2 positive breast cancer
Crown J, Collins DM, Eustace AJ, Keane M, Coate L, Kennedy J, O'Reilly S, Kelly C, O'Connor M, Martin MJ, Murphy C, Duffy K, Walshe J, Mahgoub T, Gullo G, Moulton B, Alvarez-Iglesias A, Parker I, Hennessy B. Department of Medical Oncology, Saint Vincent's University Hospital, Dublin, Ireland; Cancer Biotherapeutics, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland; Dublin City University; Department of Medical Oncology, University Hospital Galway, Galway, Ireland; Department of Medical Oncology, University Hospital Limerick, Limerick, Ireland; Department of Medical Oncology, St James's Hospital, Dublin, Ireland; Department of Medical Oncology, Cork University Hospital, Cork, Ireland; Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland; Department of Medical Oncology, University Hospital Waterford, Waterford, Ireland; Department of Medical Oncology, Sligo University Hospital, Sligo, Ireland; Department of Medical Oncology, Bon Secours Cork Cancer Centre, Cork, Ireland; Department of Medical Oncology, Letterkenny University Hospital, Donegal, Ireland; Dept. of Medical Oncology St. Vincent's University Hospital and Tallaght University Hospital; Department of Medical Oncology, University Hospital Limerick, Limerick, Ireland; Regeneron Pharmaceuticals; Clinical Oncology Development Europe; HRB- Clinical Research Facility, Galway, Ireland; Cancer Trials Ireland, Dublin, Ireland; Department of Medical Oncology, ICORG/Cancer Trials Ireland, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland.
P1-11-10 Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines
Ashfield N, Mahdi AF, Conlon NT, Crown J, Collins DM. Cancer Biotherapeutics, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland; Department of Medical Oncology, Saint Vincent's University Hospital, Dublin, Ireland.
P1-11-11 HER2-directed therapy in early breast cancer – improvement over 20 years
Engel J, Reinhardt K, Strauß H-G, Große R, Barrot S, Bauer M, van Uden L, Kaufhold S, Schüler K, Wieder V, Kantelhardt EJ, Vetter M, Thomssen C. Martin-Luther-University Halle-Wittenberg, Dept.of Gynecology; Martin-Luther-University Halle-Wittenberg, Institute of Pathology.
P1-11-12 Soluble TNFα blockade enhances trastuzumab deruxtecan antitumor effect in HER2-positive breast cancer model
Bruni S, Mauro FL, Proietti C, Cordo Russo R, Mercogliano MF, Schillaci R. Instituto de Biología y Medicina Exprerimental, Buenos Aires, Argentina.
P1-11-13 DE-REAL: Italian multicenter experience of Trastuzumab Deruxtecan in a real world setting
Botticelli A, Scagnoli S, Pisegna S, Santini D, Palazzo A, Scafetta R, Rossi L, de Laurentiis M, Caputo R, Verrazzo A, Berardi R, Barberi V, Bilancia D, D'auria G, Alesini D, Palleschi M, Fabbri A, Strigari L, Preissner R, Marchetti P, Fabi A. Policlinico Umberto I Rome - Italy; Sapienza University of Rome; Fondazione Policlinico Universitario A. Gemelli IRCCS Rome - Italy; Università Campus Bio-Medico di Roma; Istituto Nazionale Tumori "Fondazione Pascale"; Fondazione Pascale IRCCS; IRCCS "Fondazione Pascale"; Ospedali Riuniti di Ancona; Azienda Ospedaliera Regionale San Carlo; Ospedale Sandro Pertini; Ospedale Santo Sprito; Department of Medical Oncology, IRCCS- Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy; Ospedale Belcolle; Università di Bologna; Charitè University of Berlin; IRCSS IDI Istituto Dermatopatico dell'Immacolata; Precision Medicine in Breast Cancer, Fondazione Policlinico Universitario A. Gemelli,IRCCS Rome - Italy.
P1-11-14 Withdrawn
P1-11-15 Withdrawn
P1-11-16 Treatment with tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A real-world study
Yin Y, Li W, Huang X, Sun C, Hua Y, Jin N, Wu X. The First Affiliated Hospital of Nanjing Medical University; Jiangsu Hospital The First Affiliated Hospital With Nanjing Medical University.
P1-11-17 The real-world outcome of human epidermal growth factor type-2 positive breast cancer patients receiving neoadjuvant therapy with or without pertuzumab
Acevedo F, Walbaum B, Medina L, Merino T, Bauerle C, Camus M, Leon A, Manzor M, Veglia P, Martinez R, Guerra C, Navarro M, Dominguez F, Sanchez C. Pontificia Universidad Catolica de Chile; Breast Surgeon at Hospital Sotero del Rio; Hospital Sotero del RIo.
P1-11-18 The efficacy and safety of trastuzumab and pertuzumab in combination with different chemotherapy regimens for neoadjuvant treatment of HER2-posotive breast cancer: a multi-center real-world study in China
Qi X, Hu H, Wenlin C, Yan X, Shu L, Yanman F, Li T, Jia M, Sihai Z, Fan C, Yueyang L, Yuanming F, Zhang Y, Tang P, Jun J, Jianyun N, Chen L, Wang S. Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Breast Surgery, the Second Affiliated Hospital of Jinan University, Shenzhen People's Hospital; Department of Breast Surgery, Breast Cancer Clinical Research Center, Cancer Hospital, Kunming Medical University; Department of Breast and Thyroid Surgery, Daping Hospital, Army Medical University; Department of Breast Surgery, The Affiliated Hospital of Guizhou Medical University; Guiyang Maternal and Child Health Care Hospital; Breast and Thyroid Surgery, Department of General Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, China; Department of Breast, Thyroid, and Pancreas Surgery, the Second Affiliated Hospital of Chongqing Medical University; Department of General Surgery, Yongchuan Hospital of Chongqing Medical University; Breast and Thyroid Surgical Department, Chongqing General Hospital, University of Chinese Academy of Sciences; Department of Breast Surgery, The Third Affiliated Hospital of Chongqing Medical University; Department of General Surgery ,The People's Hospital of Changshou District; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Breast Surgery, Breast Cancer Clinical Research Center, Cancer Hospital, Kunming Medical University; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University.
P1-11-19 A real-world evidence study of treatment patterns in patients with HER2-positive metastatic breast cancer who have received at least 2-lines of therapy
Varghese D, Cruz GI, Johanson C, Toland L, Miranda M, Faherty EC, Harland D, Kaplan HG. AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, USA; Syapse; AstraZeneca PLC; Swedish Cancer Institute.
P1-11-20 Trastuzumab (HLX02) plus Pertuzumab as dual-target neoadjuvant therapy for HER2-positive breast cancer: A real-world study
Liu Y, Zuo W-J, Wang R-X, Wang Z-H, Shao Z-M. Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University.
P1-11-21 Withdrawn
   
  Treatment - Therapeutic Strategies: Toxicities - Management
P1-12-01 Impact of anti-estrogen therapy on early vascular referrals, tests and medications in premenopausal women with operable breast cancer
Ansari A, Levine B, Douglas E, Ansley K, Melin S, Park C, Richardson K, D'Agostino R, Jordan J, Thomas A. Atrium Health Wake Forest Baptist Health; Wake Forest School of Medicine; VCU.
P1-12-02 Unusual hepatotoxicity with the use of Ribociclib in a premenopausal patient
Carlos G, Zucchetti B, Donatelli V, Carlos A, Ferrari A, Cruz M, Dagostim C. DASA.
P1-12-03 Antidiarrheal prophylaxis with loperamide for patients with lymph node-negative (N0) or micrometastatic (N1mi), HER2-positive breast cancer who received adjuvant pyrotinib plus nab-paclitaxel: a randomized sub-study of PHAEDRA
Wang C, Lin Y, Zhou Y, Mao F, Guan J, Shen S, Wang X, Zhang X, Zhang Y, Pan B, Zhong Y, Peng L, Li Y, Huang X, Xu Y, Sun Q. Peking Union Medical College Hospital.
P1-12-04 Side effects of the mRNA COVID-19 vaccines in women treated for breast cancer
Juhel B, Brunelle CL, Bernstein MC, Smith LH, Jung AW, Hausman EK, Bucci LK, Naoum GE, Taghian AG. Lymphedema Research Program, Massachusetts General Hospital; Massachusetts General Hospital; Adelphi Values; Massachusetts General Hospital; Roux Institute at Northeastern University; MGH; New York Institute of Technology College of Osteopathic Medicine; Northwestern University Memorial Hospital; Massachusetts General Hospital/Harvard Medical School.
P1-12-05 The impact of adjuvant chemotherapy, including taxanes, on breast cancer-related lymphedema risk
Jung AW, Juhel B, Smith LH, Brunelle CL, Hausman EK, Bucci LK, Naoum GE, Taghian AG. Lymphedema Research Program, Massachusetts General Hospital; Massachusetts General Hospital; Roux Institute at Northeastern University; Massachusetts General Hospital; MGH; New York Institute of Technology College of Osteopathic Medicine; Northwestern University Memorial Hospital; Massachusetts General Hospital/Harvard Medical School.
P1-12-06 Prevalence and spectrum of manifestations of Tamoxifen retinopathy as assessed by multimodal and ultra-widefield retinal imaging
Zhao E, Kovacs K. Weill Cornell Medical College.
P1-12-07 Management of genitourinary symptoms in breast cancer patients: An updated systematic review of available evidence from randomized trials
Fallah P, Wolfe DM, Hutton B, Clemons M, Shorr R, Vandermeer L, Rushton-Marovac M. Division of Medical Oncology, and Department of Medicine, Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute; Ottawa Hospital; Ottawa Hospital and Cancer Center-General Campus.
P1-12-08 Biomarker analysis of hepatotoxicity in a Phase II study of nivolumab, abemaciclib and endocrine therapy in patients with HR-positive, HER2-negative breast cancer: WJOG11418BTR NEWFLAME_TR
Tsurutani J, Masuda J, Masuda N, Tanabe Y, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Yoshimura K, Takano T, Kawabata H. Advanced Cancer Translational Research Institute at Showa University, Tokyo, Japan; JFCR; Nagoya University Graduate School of Medicine, Department of Surgery, Breast Oncology NHO Osaka National Hospital; Toranomon Hospital; Kindai University Hospital; Hokkaido University, Sapporo, Japan; Breast Surgery, Gifu University Hospital; Hyogo Cancer Center; Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center; Aichi Cancer Center Hospital, Aichi, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Showa University; Hiroshima University Hospital; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital.
P1-12-09 Withdrawn
P1-12-10 Superior effectiveness of Plinabulin (Plin) versus no-treatment for Docetaxel (Doc)-induced neutropenia (N) and other hematologic complication in breast cancer (BC) patients
Blayney D, Wells J, Duprez S, Legaspi G, Huang L, Mohanlal R. BeyondSpring Pharmaceuticals, Inc.
P1-12-11 Real-world incidence and management of diarrhea secondary to pyrotinib in patients with HER-2 positive breast cancer
Liu H, Ma L, Wang X, Chang X, Yu Q, Huang Q, Hao C, Liu J, Zhao J, Li S, Tong Z, Shi Y, Lu N, Zhao W, Wang T, Cao X, Wang C, Liu J, Zhao Y, Zhang L, Guo B, Wang X, Di X, Gao C, Liu Z, Sun S, Li L. Tianjin Medical University Cancer Institute and Hospital; The Fourth Hospital of Hebei Medical University; Tianjin Jinghai Hospital; Department of Breast Medical Oncology, Tianjin Medical University Cancer Institute and Hospital; The Second Affiliated Hospital of Harbin Medical University; The Forth Central Hospital of Tianjin; Baoding First Central Hospital; Tumor Hospital of Jining; Chinese People's Liberation Army (PLA) NO.983 Hospital.
P1-12-12 Adverse events associated with breast cancer vaccines
Dowding R, Liu Y, Childs JS, Disis M. UW Medicine Cancer Vaccine Institute.
   
  Tumor Cell and Molecular Biology: Drug Resistance
P1-13-01 Targeting RRM2 for the treatment of palbociclib resistant breast cancer
Sultana N, Elford HL, Faridi JS. University of The Pacific; Molecules for Health Inc.
P1-13-02 The aberrant activity of retrotransposon elements mediates the chemo-tolerant persister cells relapse in TNBC
Zhang Z, Wang Y, Luo X, Li X, Zhan X, Zheng Y, Ding J, Wu T. Baylor College of Medicine; McGill University.
P1-13-03 Establishment and characterization of two T-DM1-resistant, ER+/HER2+ breast XPDX models developed sequentially from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)
Plasko G, Flores J, Simonson A, Forofontov P, Varma A, Lang A, Rodriguez G, Papadopoulos KP, Rasco D, Patnaik A, Conway B, Johnston J, Wick M. XenoSTART; The START Center; START San Antonio.
P1-13-04 Potentiating alpelisib in PI3K pathway overactive triple negative breast cancers
Boyd D, Harrell C. Virginia Commonwealth University.
P1-13-05 Extracellular vesicles-transported lncRNA BCDR1 promotes tumor cell proliferation and therapy resistance via upregulating G1/S-phase transition in breast cancer
Zhang Q, Xiu B, Chi Y, Wu J. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China.
P1-13-06 Loss of emerging tumor and metastasis suppressor RasGAPs mediates therapeutic resistance in HER2+ breast cancer
Perurena N, Pilla N, Schade A, Watanabe M, Loi P, Rodriguez CL, Gardner AM, Cichowski K. Brigham and Women's Hospital, Harvard Medical School; Brigham and Women's Hospital; Harvard University; Harvard Medical School.
P1-13-07 Investigating NF1 mutations in circulating tumor DNA of patients with hormone-receptor positive (HR+) breast tumors resistant to CDK4/6 inhibition (CDK4/6i): A retrospective clinical analysis
Lloyd MR, Ryan L, Medford AJ, Keenan JC, Spring LM, Vidula N, Moy B, Juric D, Ellisen LW, Bardia A, Wander SA. Beth Israel Deaconess Medical Center; Cancer Center, Massachusetts General Hospital; Massachusetts General Hospital Cancer Center / Dana Farber Cancer Institute; Massachusetts General Hospital Cancer Center, Boston, MA, USA; Harvard Medical School, Massachusetts General; Massachusetts General Hospital; Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, MA, USA; Cancer Center, Massachusetts General Hospital; Massachusetts General Hospital Cancer Center.
P1-13-08 Inhibition of RNA binding protein HuR function sensitizes the TNBC to chemotherapy
Wei L, Zhang Q, Zhong C, Aubé J, Welch DR, Wu X, Xu L. Bioengineering Program, The University Of Kansas; Department of Molecular Biosciences, The University Of Kansas; Department of Electrical Engineering and Computer Science, The University Of Kansas; Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, The University of North Carolina; Department of Cancer Biology, The University of Kansas Medical Center; Department of Molecular Biosciences, The University Of Kansas.
P1-13-09 Withdrawn
P1-13-10 Deconvoluting dynamics of acquired chemoresistance in triple negative breast cancer tumors
Kumar P, Menghi F, Straub R, Mukashyaka P, Lloyd MW, Chandok H, George J, Chuang J, Liu E. The Jackson Laboratory for Genomic Medicine.
P1-13-11 YES1 is a targetable vulnerability for improving taxane response in triple-negative breast cancer
Ingles N, Piemonte K, Singh S, Weber-Bonk K, Keri R. Case Western Reserve University; Cleveland Clinic.
P1-13-12 Targeting Dynamin-related protein 1 for the management of taxane-resistant triple-negative breast cancer
Terrero D, Tiwari A, Raman D. University of Toledo.
P1-13-13 Nuclear envelope expression of the oncogene adipocyte-associated methionine domain containing conveys inferior prognosis but increased sensitivity to statins and fluorouracil-based therapy
Redfern AD, Weerasena I, Spalding L, Ong M, Golden E, Woodward E, Blancafort P. University of Western Australia; St John of God Hospital Bunbury; Harry Perkins institute for Medical Research.
P1-13-14 Increased androgen receptor expression as a mechanism of acquired anti-androgen resistance in androgen receptor-positive triple negative breast cancer
Krause H, Sharifi MN, Wolfe SK, Sperger JM, Wisinski KB, O'Regan R, Lang J. Department of Medicine, University of Wisconsin, Madison; University of Wisconsin Carbone Cancer Center; Department of Medicine, University of Wisconsin, Madison; University of Rochester Medical Center.
P1-13-15 Elevated TCEAL9 expression is correlated with trastuzumab-based neoadjuvant chemotherapy resistance in HER2-positive breast cancer
Goh CW, Chi W-R, Zhang L, Zhang Q, Chen M, Xiong M, Liu D, Ren H, Xiu B, Xue J, Chi Y, Wu J. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China; Fudan University Shanghai Cancer Center,Shanghai China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China.
P1-13-16 Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
Lorman-Carbó N, Martínez-Sáez O, Fernandez-Martinez A, Galván P, Chic N, Adamo B, Vidal M, Muñoz M, Perou CM, Gavilá J, Pascual T, Prat A, Brasó-Maristany F. Institut d'Investigacions Biomediques August Pi I Sunyer; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Hospital Clínic of Barcelona, Barcelona, Spain ; August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Medical Oncology Department, Hospital Clínic de Barcelona ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Medical Oncology Department, Hospital Clínic of Barcelona ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; SOLTI Breast Cancer Research Group ; Faculty of Medicine and Health Sciences, University of Barcelona; SOLTI Breast Cancer Research Group, Hospital Clínic of Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain ; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain / SOLTI Cancer Research Group, Barcelona, Spain; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain ; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Breast Cancer Unit, IOB-Quirón Salud, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS).
P1-13-17 Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models
Liao F-T, Gordon T, Liu CC, Selenica P, Zhu Y, Patel J, Nanda S, Qin L, Fu X, Gazzo A, Marra A, Blanco-Heredia J, Weigelt B, Reis-Filho J, Osborne CK, Rimawi MF, Schiff R, Veeraraghavan J. Baylor College of Medicine, Houston, TX, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine.
P1-13-18 EGFR signaling contributes to acquired resistance to CDK4/6 inhibitors in ER+ breast cancer cells in vitro and in vivo
Lypova N, Lanceta L, Daugherty S, Chesney J, Imbert-Fernandez Y. University of Louisville.
P1-13-19 ESAM reduces anti-HER2 therapy sensitivity by activating mTOR pathway in HER2 positive breast cancer
Wu J, Zhou X, Chi Y, Xue J. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China.
P1-13-20 Reprogramming of oncogenic signal pathways and metabolism during trastuzumab resistance formation of HER2 positive breast cancer
Duan N, Hua Y, Hu S, Yin Y. The First Affiliated Hospital of Nanjing Medical University; Nanjing Maternity and Child Health Care Hospital.
P1-13-21 Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in luminal breast cancer cells
Cordani N, Mologni L, Piazza R, Cogliati V, Pepe F, Capici S, Di Bella C, Jaconi M, Cerrito MG, Villa M, Tettamanti P, Cavaletti G, Lavitrano M, Cazzaniga ME. University of Milano Bicocca; ASST-Monza; University of Pavia; University of Milano Bicocca / ASST-Monza.
P1-13-22 Establishment and characterization of two ER+/HER2- XPDX models developed sequentially before and after acquired resistance to the CDK4/6 inhibitor palbociclib from a patient with metastatic breast cancer
Varma A, Flores J, Simonson A, Stackpole A, Papadopoulos KP, Patnaik A, Rasco D, Beeram M, Sandera M, Wick M. XenoSTART; START San Antonio.
P1-13-23 Carboplatin resistance-associated changes in the 3D chromatin landscape of a triple-negative breast cancer Patient-Derived Xenograft
Dozmorov M, Marshall M, Rashid N, Grible J, Valentine AD, Olex A, Murthy K, Chakraborty A, Reyna J, Salgado Figueroa D, Lee D-A, Baur B, Roy S, Ay F, Harrell C. Virginia Commonwealth University; Virginia Commonwealth University, C. Kenneth and Diane Wright Center for Clinical and Translational Research; La Jolla Institute for Immunology; University of Wisconsin-Madison; Department of Pathology, Virginia Commonwealth University, Richmond, VA, USA.
   
  Treatment - Types and Sites of Breast Cancer: Other
P1-14-01 Incidence, clinicopathological features and treatment outcomes of young breast cancer patients: A cohort analysis from a high-volume tertiary cancer center in the United Arab Emirates
Al-Awadhi A, Hourani M, Hussein M, Alkindi F, Wahba L, AlAgha A, Shoqeir A, Yousif A, AlShebli M, Trad D, Masih A, Azribi F, Luiten E, Al-Shamsi H, Toffaha K. Department of Medical Oncology -Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE; Department of Internal Medicine -Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE; Department of Clinical Pharmacy -Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE; Department of Academic affairs -Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE; American Hospital Dubai; Department of Surgical Oncology -Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE , Department of Surgery, College of Medicine and Health Sciences, UAE University, Al Ain, UAE; Industrial and Systems Engineering Department, Khalifa University, Abu Dhabi, United Arab Emirate.
P1-14-02 Breast cancer in pregnancy: A retrospective clinical study in a single large tertiary cancer center in the United Arab Emirates
Hourani M, Bdair R, Hussein M, Yousif A, Wahba L, AlAgha A, Shoqeir A, Alkindi F, Alawadhi A. Tawam Hospital; United Arab Emirates University; Department of Medical Oncology -Tawam hospital - Abu Dhabi Health Services Company - Al Ain - UAE.
   
  Treatment - Types and Sites of Breast Cancer: Brain Metastases
P1-14-03 Efficacy and safety of pyrotinib-based therapy in the treatment of HER2-positive breast cancer patients with brain metastases:a multi-center real-world study
Li H, Huang J, Tan Q, Man X, Yin S, Sun S, Hu Y, Li W, Zhou D, Song L, Zhang B, Xu L, Wang X, Xie X. Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute; Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University; Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital.
P1-14-04 A phase 0 clinical trial of Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent blioblastoma
Ghamasaee P, Balinda H, Brenner A, Floyd J. UT Health San Antonio; UT Health Science Center at San Antonio.
   
  Treatment - Types and Sites of Breast Cancer: Inflammatory Breast Cancer
P1-14-05 Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients with Chest Wall Breast Cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1)
Valenza C, Berton Giachetti PPM, Zagami P, Nicolò E, Trapani D, Boldrini L, Taurelli Salimbeni B, Ascione L, Antonarelli G, Corti C, Esposito A, Criscitiello C, Fusco N, Curigliano G. European Institute of Oncology, IRCCS, University of Milano, Milan, Italy; University of Milan, Milan, Italy.